Esperion Therapeutics (ESPR) Equity Ratio (2018 - 2025)
Historic Equity Ratio for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to 1.24.
- Esperion Therapeutics' Equity Ratio fell 520.57% to 1.24 in Q3 2025 from the same period last year, while for Sep 2025 it was 1.24, marking a year-over-year decrease of 520.57%. This contributed to the annual value of 1.13 for FY2024, which is 4886.27% up from last year.
- Per Esperion Therapeutics' latest filing, its Equity Ratio stood at 1.24 for Q3 2025, which was down 520.57% from 1.25 recorded in Q2 2025.
- Over the past 5 years, Esperion Therapeutics' Equity Ratio peaked at 0.52 during Q4 2021, and registered a low of 2.21 during Q4 2023.
- Moreover, its 5-year median value for Equity Ratio was 1.18 (2024), whereas its average is 1.21.
- Per our database at Business Quant, Esperion Therapeutics' Equity Ratio tumbled by 461013.19% in 2021 and then surged by 4886.27% in 2024.
- Esperion Therapeutics' Equity Ratio (Quarter) stood at 0.52 in 2021, then tumbled by 153.02% to 1.31 in 2022, then plummeted by 69.3% to 2.21 in 2023, then soared by 48.86% to 1.13 in 2024, then dropped by 9.67% to 1.24 in 2025.
- Its Equity Ratio was 1.24 in Q3 2025, compared to 1.25 in Q2 2025 and 1.32 in Q1 2025.